Literature DB >> 6437461

High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients.

M J Deegan, J P Abraham, M Sawdyk, E J Van Slyck.   

Abstract

Chronic lymphocytic leukemia (CLL) is generally considered a nonsecretory B cell immunoproliferative disorder. Conventional electrophoretic and immunoelectrophoretic methods have revealed serum monoclonal proteins in less than 10% of these patients. However, there is increasing experimental evidence from in vitro studies demonstrating that CLL cells may secrete immunoglobulins, particularly free light chains. We examined the serum and urine of 36 consecutive CLL patients for monoclonal proteins using sensitive immunochemical methods (high resolution agarose gel electrophoresis combined with immunofixation). The results obtained were correlated with the Rai stage, quantitative immunoglobulin levels, and lymphocyte membrane immunoglobulin phenotype of the leukemic cells. Twenty-three monoclonal proteins were identified in the serum or urine of 22 patients, an incidence of 61%. Six patients had serum monoclonal proteins, seven had only urinary monoclonal proteins, and nine had monoclonal proteins in serum and urine. In every instance the monoclonal protein was the same light chain type as expressed on the leukemic cells. Our findings suggest that the monoclonal proteins observed in the serum or urine of CLL patients are secretory products of the tumor cells and that their discovery is a function of the sensitivity of the method used for their detection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437461

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Biclonal Gammopathy in Chronic Lymphocytic Leukemia: Case Report and Review of the Literature.

Authors:  Nafila Al-Riyami; Khalil Al-Farsi; Khalfan Al-Amrani; Sameera Al-Harrasi; Mohammed Al-Huneini; Salam Al-Kindi
Journal:  Oman Med J       Date:  2015-05

2.  Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.

Authors:  F Fais; B Sellars; F Ghiotto; X J Yan; M Dono; S L Allen; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; M Schuster; V P Vinciguerra; K Rai; F K Stevenson; P K Gregersen; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

3.  IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations.

Authors:  D G Efremov; M Ivanovski; F D Batista; G Pozzato; O R Burrone
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  A case of monoclonal gammopathy in extranodal marginal zone B-cell lymphoma of the small intestine.

Authors:  Do Yeun Kim; Yong-Seok Kim; Hee Jin Huh; Jong Sun Choi; Jeong Seok Yeo; Beom Seok Kwak; Seok Lae Chae
Journal:  Korean J Lab Med       Date:  2011-01

5.  Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Authors:  Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Brian K Link; Cristine Allmer; Clive S Zent; Timothy G Call; Kari G Rabe; Curtis A Hanson; Neil E Kay; Susan L Slager; Thomas E Witzig; Tait D Shanafelt
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

6.  Direct effect of interleukin 2 on chronic lymphocytic leukaemia B cell functions and morphology.

Authors:  V Malkovska; J Murphy; L Hudson; D Bevan
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

7.  Evaluation of CD5-positive B cells in blood and synovial fluid of patients with rheumatic diseases.

Authors:  J A Sowden; P J Roberts-Thomson; H Zola
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

Review 8.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors:  S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

9.  Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

Authors:  Huei-Ting Tsai; Neil E Caporaso; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Richard B Hayes; Gerald E Marti; Maher Albitar; Paolo Ghia; S Vincent Rajkumar; Ola Landgren
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

10.  Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.

Authors:  S Shahzad Mustafa; Saad Jamshed; Karthik Vadamalai; Allison Ramsey
Journal:  PLoS One       Date:  2021-10-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.